Form 8-K - Current report:
SEC Accession No. 0001104659-23-050654
Filing Date
2023-04-27
Accepted
2023-04-27 06:43:09
Documents
16
Period of Report
2023-04-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2313695d1_8k.htm   iXBRL 8-K 34491
2 EXHIBIT 99.1 tm2313695d1_ex99-1.htm EX-99.1 332109
3 EXHIBIT 99.2 tm2313695d1_ex99-2.htm EX-99.2 287468
8 GRAPHIC tm2313695d1_ex99-1img001.jpg GRAPHIC 12907
  Complete submission text file 0001104659-23-050654.txt   955114

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA mrk-20230427.xsd EX-101.SCH 4152
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mrk-20230427_def.xml EX-101.DEF 28239
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrk-20230427_lab.xml EX-101.LAB 38353
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrk-20230427_pre.xml EX-101.PRE 26849
10 EXTRACTED XBRL INSTANCE DOCUMENT tm2313695d1_8k_htm.xml XML 7850
Mailing Address 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033
Business Address 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033 908-740-4000
Merck & Co., Inc. (Filer) CIK: 0000310158 (see all company filings)

EIN.: 221918501 | State of Incorp.: NJ | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-06571 | Film No.: 23851755
SIC: 2834 Pharmaceutical Preparations